Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Anti-inflammatory Intervention With Dapansutrile (OLT1177®) for Parkinson's Disease Modification (DAPA-PD): A Randomised Double-Blind, Placebo-Controlled Phase II Trial

NCT07157735 is registered in ClinicalTrials.gov with Cambridge University Hospitals NHS Foundation Trust as lead sponsor.

NCT NCT07157735
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07157735 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Anti-inflammatory Intervention With Dapansutrile (OLT1177®) for Parkinson's Disease Modification (DAPA-PD): A Randomised Double-Blind, Placebo-Controlled Phase II Trial
Lead sponsor
Cambridge University Hospitals NHS Foundation Trust
Phase
Phase 2
Overall status
Recruiting
Start date
February 2, 2026
Completion date
June 30, 2028
Enrollment
36 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

parkinson disease